2004 Guide to Psychiatric Drug Interactions

Sheldon H. Preskorn, David Flockhart

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Why should physicians be concerned about drug-drug interactions (DDIs)? DDIs have the potential for causing untoward outcomes, including morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. A recent survey found that 10% of all Americans >18 years of age were taking five or more prescription medications. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medication. In addition, medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of psychiatric medications must consider all of the medications the patient is taking. This educational review discusses major pharmacologic principles to guide the safe and effective use of multiple medications with a focus on neuropsychiatric medications. It also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

Original languageEnglish
Pages (from-to)39-60
Number of pages22
JournalPrimary Psychiatry
Volume11
Issue number2
StatePublished - Feb 2004

Fingerprint

Drug Interactions
Psychiatry
Pharmaceutical Preparations
Pharmacokinetics
Therapeutic Uses
Antidepressive Agents
Prescriptions
Morbidity
Delivery of Health Care
Physicians
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Genetics

Cite this

Preskorn, S. H., & Flockhart, D. (2004). 2004 Guide to Psychiatric Drug Interactions. Primary Psychiatry, 11(2), 39-60.

2004 Guide to Psychiatric Drug Interactions. / Preskorn, Sheldon H.; Flockhart, David.

In: Primary Psychiatry, Vol. 11, No. 2, 02.2004, p. 39-60.

Research output: Contribution to journalArticle

Preskorn, SH & Flockhart, D 2004, '2004 Guide to Psychiatric Drug Interactions', Primary Psychiatry, vol. 11, no. 2, pp. 39-60.
Preskorn SH, Flockhart D. 2004 Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2004 Feb;11(2):39-60.
Preskorn, Sheldon H. ; Flockhart, David. / 2004 Guide to Psychiatric Drug Interactions. In: Primary Psychiatry. 2004 ; Vol. 11, No. 2. pp. 39-60.
@article{17ab2b0f0a91401ab8d80083fc84f7ce,
title = "2004 Guide to Psychiatric Drug Interactions",
abstract = "Why should physicians be concerned about drug-drug interactions (DDIs)? DDIs have the potential for causing untoward outcomes, including morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. A recent survey found that 10{\%} of all Americans >18 years of age were taking five or more prescription medications. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medication. In addition, medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of psychiatric medications must consider all of the medications the patient is taking. This educational review discusses major pharmacologic principles to guide the safe and effective use of multiple medications with a focus on neuropsychiatric medications. It also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.",
author = "Preskorn, {Sheldon H.} and David Flockhart",
year = "2004",
month = "2",
language = "English",
volume = "11",
pages = "39--60",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "2",

}

TY - JOUR

T1 - 2004 Guide to Psychiatric Drug Interactions

AU - Preskorn, Sheldon H.

AU - Flockhart, David

PY - 2004/2

Y1 - 2004/2

N2 - Why should physicians be concerned about drug-drug interactions (DDIs)? DDIs have the potential for causing untoward outcomes, including morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. A recent survey found that 10% of all Americans >18 years of age were taking five or more prescription medications. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medication. In addition, medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of psychiatric medications must consider all of the medications the patient is taking. This educational review discusses major pharmacologic principles to guide the safe and effective use of multiple medications with a focus on neuropsychiatric medications. It also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

AB - Why should physicians be concerned about drug-drug interactions (DDIs)? DDIs have the potential for causing untoward outcomes, including morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. A recent survey found that 10% of all Americans >18 years of age were taking five or more prescription medications. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medication. In addition, medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of psychiatric medications must consider all of the medications the patient is taking. This educational review discusses major pharmacologic principles to guide the safe and effective use of multiple medications with a focus on neuropsychiatric medications. It also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

UR - http://www.scopus.com/inward/record.url?scp=1842560443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842560443&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:1842560443

VL - 11

SP - 39

EP - 60

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 2

ER -